- Home
- KNRX vs ENLV Comparison
KNRX vs ENLV Comparison
Compare KNRX & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KNRX | ENLV |
|---|---|---|
| Founded | 2009 | 2005 |
| Country | Singapore | Israel |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5M | 5.1M |
| IPO Year | 2023 | 2014 |
Fundamental Metrics
Financial Performance| Metric | KNRX | ENLV |
|---|---|---|
| Price | $0.18 | $0.20 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 13.6M | 1.7M |
| Earning Date | 11-03-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.15 | $0.19 |
| 52 Week High | $3.45 | $7.64 |
Technical Indicators
Market Signals| Indicator | KNRX | ENLV |
|---|---|---|
| Relative Strength Index (RSI) | 43.29 | 18.86 |
| Support Level | $0.15 | N/A |
| Resistance Level | $0.49 | $1.26 |
| Average True Range (ATR) | 0.02 | 0.04 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 21.18 | 2.48 |
Price Performance
Historical ComparisonAbout KNRX KNOREX LTD. Class A Ordinary Shares
Knorex Ltd is a B2B technology company providing programmatic advertising products and solutions to marketers to streamline and automate their advertising and marketing workflows. The company's product, Knorex XPOSM, is a self-service, enterprise-grade cloud platform with a suite of advertising management and execution (AMX) applications.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.